title: Venous thromboemboli following total joint arthroplasty: SCIP measures move us closer to an agreement.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Mont
authors.forename: William J
authors.initials: WJ
authors.lastname: Hozack
authors.forename: John J
authors.initials: JJ
authors.lastname: Callaghan
authors.forename: Viktor
authors.initials: V
authors.lastname: Krebs
authors.forename: Javad
authors.initials: J
authors.lastname: Parvizi
authors.forename: J Bohannon
authors.initials: JB
authors.lastname: Mason
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D019643:Arthroplasty, Replacement / Q000009:adverse effects*; D018890:Chemoprevention; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D048228:Intermittent Pneumatic Compression Devices; D017410:Practice Guidelines as Topic; D054556:Venous Thromboembolism / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents